Qitao Yu

Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)

Yunpeng Yang, Zhehai Wang, Jian Fang et al. · Journal of Thoracic Oncology · 2020 · 376 citations · Full text

[Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients].

Jinwan Wang, Yan Sun, Qitao Yu et al. · PubMed · 2005 · 147 citations

Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study

Yunpeng Yang, Jiya Sun, Zhehai Wang et al. · Journal of Thoracic Oncology · 2021 · 141 citations · Full text

Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706)

Hongyun Zhao, Wenxiu Yao, Xuhong Min et al. · Journal of Thoracic Oncology · 2021 · 116 citations

Apatinib Plus Gefitinib, Medicine, Advanced Egfr-mutant Nsclc +8

Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study

Yuankai Shi, Xingsheng Hu, Shucai Zhang et al. · The Lancet Respiratory Medicine · 2021 · 115 citations

Genetic Analysis, Egfr T790m, Phase 2B +12